Medicilon attended the 21st China International Fair for Investment and Trade and signed a strategic collaboration agreement with Xiamen Biotime.
On September 8th to 11th, the 21st China International Fair for Investment and Trade (CIFIT) was held in Xiamen, Fujian Province.
As the leading one-stop preclinical R&D CRO in China, Shanghai Medicilon Inc. (Medicilon) was invited to participate in this conference. During the conference, Dr. Chunlin Chen, the founder & CEO of Medicilon, and Huang Jianguo, Deputy General Manager of Xiamen Biotime Biotechnology Co., Ltd. (Biotime), signed a strategic collaboration agreement.
Signing the Strategic Agreement
The CIFIT is sponsored by the Ministry of Commerce and co-organized by international organizations such as the United Nations Conference on Trade and Development (UNCTAD), the United Nations Industrial Development Organization (UNIDO), the Organization for Economic Cooperation and Development (OECD), the World Bank International Finance Corporation (IFC), and the World Association of Investment Promotion Agencies (WAIPA). CIFIT is currently the only international investment promotion activity aimed at promoting two-way investment in China. CIFIT is also the world’s largest investment exhibition certified by the Global Association of the Exhibition Industry (UFI).
Medicilon was invited to attend the conference, together with the companies and institutions in the biotechnology field of the BRICS countries, to focusing on new directions, new technologies and new platforms. Furthermore, CIFIT also serves as a platform to demonstrate the latest achievements of BRICS collaboration in the pharmaceutical industry, to accelerate the transformation and upgrading of the pharmaceutical industry, and to achieve the development together.
During the conference, Medicilon and Biotime reached a consensus on deepening strategic collaboration. In the collaboration agreement, the two parties will use an efficient, functional and innovative collaboration model to fully utilize the advantages of Medicilon’s one-stop preclinical R&D and the advantages of Biotime’s leading in vitro diagnostic products and services to jointly build the CRO+CDMO industry service chain, to enhance the biopharmaceutical R&D and production service capabilities, and to help the innovation and development of the global biopharmaceutical industry.
Medicilon wishes that Biotime could use Medicilon’s high-quality innovative R&D technology service platform and resources to develop more products in the future. Medicilon also wished to be the most reliable strategic partner in the development of Biotime.
Established in April 2008, Xiamen Biotime Biotechnology Co., Ltd. is a hi-tech enterprise that specialized in R&D, production, and sales of POCT in vitro diagnostic devices and reagents. Biotime has successfully established the mature medical marketing channels during the past years. With the leading technologies, Biotime aims to develop superior IVD products that provide better solutions for health care and benefit people all over the world.
Since the founding of our company in 2004, Medicilon (Stock Code: 688202.SH) has grown into one of the professional drug discovery contract research organizations (CRO) in China. Over the years, Medicilon keeps improving their services in biotechnology and pharmaceutical research. Their services now span across medicinal chemistry, process chemistry, in vitro and in vivo DMPK, preclinical development and bioanalytical support. Medicilon grows together with the clients and delivers the new drug research and development services to more than 900 clients globally. Medicilon is proud to contribute to human health in the globe.